ADC Therapeutics (ADCT) Amortization - Deferred Charges (2019 - 2023)
Historic Amortization - Deferred Charges for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$12.9 million.
- ADC Therapeutics' Amortization - Deferred Charges fell 1396.62% to -$12.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$39.2 million, marking a year-over-year decrease of 9459.8%. This contributed to the annual value of -$36924.0 for FY2022, which is 30380.86% down from last year.
- ADC Therapeutics' Amortization - Deferred Charges amounted to -$12.9 million in Q3 2023, which was down 1396.62% from -$15.9 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Amortization - Deferred Charges registered a high of $9165.0 during Q1 2022, and its lowest value of -$15.9 million during Q2 2023.
- In the last 5 years, ADC Therapeutics' Amortization - Deferred Charges had a median value of -$897000.0 in 2020 and averaged -$4.1 million.
- Its Amortization - Deferred Charges has fluctuated over the past 5 years, first crashed by 606240000.0% in 2020, then skyrocketed by 36241.17% in 2022.
- Over the past 5 years, ADC Therapeutics' Amortization - Deferred Charges (Quarter) stood at -$51.0 in 2019, then plummeted by 3803821.57% to -$1.9 million in 2020, then soared by 99.51% to -$9520.0 in 2021, then dropped by 2.98% to -$9804.0 in 2022, then plummeted by 131907.34% to -$12.9 million in 2023.
- Its Amortization - Deferred Charges was -$12.9 million in Q3 2023, compared to -$15.9 million in Q2 2023 and -$10.4 million in Q1 2023.